# How does CD80/CD86 blockade by abatacept affect T-cell activation and tolerance?

## Abstract

CD80/CD86 blockade by abatacept consistently reduces T-cell activation across multiple disease contexts through selective modulation of CD28-mediated costimulation. Treatment decreases expression of activation markers (CD38, ICOS, Ki-67) and reduces proliferation particularly in CD4+ T cells, with 7-10-fold fewer proliferating and activated effector memory CD4+ T cells observed in GVHD prevention. Abatacept shifts CD4+ compartments toward naive phenotypes while reducing central memory populations, with transcriptional analysis revealing decreased expression of genes regulating cell cycle and chromatin dynamics.

## Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria:
- **Abatacept Intervention**
- **T-cell Outcomes**
- **Control Groups**
- **Study Design**
- **Intervention Isolation**
- **Study Setting**
- **Publication Status**
- **Intervention Specificity**

## Results

### Characteristics of Included Studies

| Study                 | Full text retrieved? | Disease context                                           | Study design                                  | Abatacept regimen                          | Primary T-cell measures                     |
|-----------------------|---------------------|----------------------------------------------------------|----------------------------------------------|--------------------------------------------|---------------------------------------------|
| J. Kremer et al., 2006| Yes                 | Rheumatoid arthritis with inadequate methotrexate response| Randomized, double-blind, placebo-controlled | ~10 mg/kg IV monthly for 1 year            | Not specified                              |
| M. Weisman et al., 2006| No                 | Active rheumatoid arthritis with inadequate methotrexate response| Phase II trial                             | 10 mg/kg or 2 mg/kg for 12 months          | Inflammatory biomarkers (IL-6, soluble IL-2 receptor)|
| Divya Koura et al., 2013| Yes               | Acute GVHD prevention during unrelated-donor HCT        | First-in-disease trial                      | 10 mg/kg IV on days -1, +5, +14, +28 post-HCT| Ki-67 proliferation, CD38/HLA-DR activation, FoxP3+ Tregs|
| M. Eichmann et al., 2020| No                 | New-onset type 1 diabetes                                | Clinical trial                              | Not specified                               | CD4+ and CD8+ naive and memory subsets by flow/mass cytometry|
| R. Alten, 2007       | No                  | Rheumatoid arthritis unresponsive to DMARDs or TNF-blockers| Review of trials                            | ~10 mg/kg at weeks 0, 2, 4, then every 4 weeks for 6-12 months| Not specified                              |
| T. Orbán et al., 2014| Yes                 | Recent-onset type 1 diabetes                              | Phase 2 trial                              | 10 mg/kg IV every 28 days for 24 months    | CM and naive CD4 T cells, CD4+CD25high Tregs, CD69 activation|
| A. Parulekar et al., 2013| No              | Mild atopic asthma                                        | Randomized, placebo-controlled, double-blind trial| 3 months of treatment                       | Naive vs. memory CD4+ T cells               |
| B. Watkins et al., 2021| No                | Severe acute GVHD following unrelated-donor HCT          | Phase II trial, randomized and single-arm   | CNI/MTX plus abatacept, measured at day +100 and +180| T-cell activation (method not specified)    |
| S. Glatigny et al., 2019| Yes              | Relapsing-remitting multiple sclerosis                    | Phase II, double-blind, placebo-controlled trial| Weeks 0, 2, 4, then every 4 weeks through week 24| Tfh and Treg frequency, CD38/ICOS activation, transcriptional profiling|
| M. Bonelli et al., 2016| No               | Rheumatoid arthritis                                      | In vivo clinical analysis and ex vivo experiments| Not specified                               | Treg frequency/function, CD95 expression, activation markers|

### Effects on T-cell Activation

#### Activation Marker Expression

Abatacept treatment reduced expression of multiple T-cell activation markers across disease contexts. In GVHD prevention, CD4+ T cells showed 7-fold fewer proliferating cells (Ki-67+) and 10-fold fewer activated cells (CD38+/HLA-DR+) at day +28 compared to controls, with effects concentrated in effector memory populations.

#### Proliferation and Cell Cycle Effects

Transcriptional analysis revealed that abatacept disrupted cell cycle and proliferation pathways in activated T cells. In multiple sclerosis patients, abatacept reduced expression of genes regulating cell cycle and chromatin dynamics during cell proliferation.

### Effects on T-cell Subset Distribution

| Study                 | Context            | Naive T cells               | Memory T cells               | Specialized subsets             | Effect magnitude                     |
|-----------------------|-------------------|-----------------------------|-------------------------------|--------------------------------------|---------------------------------------|
| T. Orbán et al., 2014 | Type 1 diabetes    | Increased naive CD4+ T cells | Decreased central memory CD4+ T cells| Reduced CD4+CD25high Tregs        | Significant reduction in absolute CM numbers|
| M. Eichmann et al., 2020| Type 1 diabetes   | Ag-naive subsets increase    | Ag-experienced subsets decrease| Not specified                        | CD4+ affected, CD8+ not affected      |
| A. Parulekar et al., 2013| Asthma           | Increased naive CD4+ T cells | Decreased memory CD4+ T cells | Not specified                        | Not quantified                        |
| S. Glatigny et al., 2019| Multiple sclerosis | No effect on CD45RA+ naive Tregs| Decreased CD45RO+ memory Tregs| Decreased Tfh frequency; reduced CD38+/ICOS+ activation| Progressive Tfh decline               |
| M. Bonelli et al., 2016| Rheumatoid arthritis| Not specified               | Not specified                 | Increased Treg numbers; diminished Treg suppressive function| Not quantified                       |

### Effects on Regulatory T Cells and Tolerance

In rheumatoid arthritis, total Treg numbers increased, but functional suppression assays revealed diminished capacity to suppress responder T-cell proliferation. The results indicate that abatacept affects regulatory T cells differently depending on context.

## Temporal Dynamics of Effects

| Study                 | Context            | Onset of activation effects  | Peak effects                | Reversibility                     | Duration assessed                    |
|-----------------------|-------------------|------------------------------|-----------------------------|-------------------------------------|--------------------------------------|
| Divya Koura et al., 2013| GVHD              | Day +28                      | Day +28                     | Yes, effects diminished after treatment cessation| Through day +100                    |
| T. Orbán et al., 2014 | Type 1 diabetes    | Within first 6 months        | 6, 12, and 24 months        | Yes, returned to baseline 6 months post-treatment| 30 months (24 + 6 follow-up)        |
| S. Glatigny et al., 2019| Multiple sclerosis | Treg changes at 4 weeks; Tfh at 16 weeks| Not specified               | Yes, reversed upon discontinuation| 52 weeks                            |
| J. Kremer et al., 2006| Rheumatoid arthritis| By 6 months                  | Up to 1 year                | Not assessed                        | 1 year                              |

## Mechanistic Insights into Activation vs. Tolerance

Abatacept’s mechanism extends beyond simple CD80/CD86 blockade to affect multiple cellular processes. The selective decrease in activated (CD38+/ICOS+) Tfh and Treg cells indicated that abatacept preferentially affected cells requiring ongoing costimulation.

## Study Quality and Limitations

Several factors affect interpretation of these findings across studies, including sample size limitations, confounding medications, and technical limitations in measurements.